We were delighted to catch up with Dr Manali Kamdar (University of Colorado, Boulder, CO, USA) to discuss the results of the randomized phase III TRANSFORM study of lisocabtagene maraleucel CAR-T cell therapy versus standard of care chemotherapy followed by ASCT in patients with relapsed or refractory large b-cell lymphoma.
Question
Please can you summarise the aims, design, eligibility criteria and efficacy and safety findings of the TRANSFORM study?
Speaker Disclosure: Manali Kamdar discloses research support/funding from TG Therapeutics, Genentech and Novartis; Consultancy to AbbVie, AstraZeneca, Celgene/Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics and Beigene; speaker’s bureau to SeaGen and DMC to Celgene and Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
